ICU Medical, Inc. (NASDAQ:ICUI) Receives $173.00 Average Target Price from Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $173.00.

Several equities research analysts have weighed in on ICUI shares. Raymond James increased their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp lifted their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price target on the stock.

ICU Medical Stock Down 0.2 %

Shares of ICU Medical stock opened at $168.46 on Monday. The stock has a market capitalization of $4.12 billion, a price-to-earnings ratio of -36.86 and a beta of 0.66. ICU Medical has a twelve month low of $83.26 and a twelve month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The business’s 50 day simple moving average is $176.22 and its 200-day simple moving average is $145.10.

Insider Buying and Selling at ICU Medical

In related news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The trade was a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,502 shares of company stock valued at $6,573,496. Company insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several hedge funds have recently made changes to their positions in ICUI. Silvercrest Asset Management Group LLC lifted its position in shares of ICU Medical by 109.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after acquiring an additional 145,485 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of ICU Medical by 2,966.3% during the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock worth $16,844,000 after purchasing an additional 137,222 shares during the period. Millennium Management LLC lifted its holdings in shares of ICU Medical by 327.8% during the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after purchasing an additional 104,264 shares during the last quarter. FMR LLC boosted its position in shares of ICU Medical by 2,676.6% in the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares during the period. Finally, Granite Investment Partners LLC purchased a new position in ICU Medical in the 2nd quarter worth about $10,650,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.